These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9375912)

  • 1. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy.
    Pernat A; Pohar B; Horvat M
    J Electrocardiol; 1997 Oct; 30(4):341-4. PubMed ID: 9375912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.
    Adler A; Fourey D; Weissler-Snir A; Hindieh W; Chan RH; Gollob MH; Rakowski H
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28550094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
    Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
    J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Danger of use of disopyramide in patients with hypertrophic obstructive cardiomyopathy. An electrophysiologic study.
    Miyajima S; Aizawa Y; Matsuoka A; Okabe M; Shibata A
    Jpn Heart J; 1988 Jan; 29(1):115-9. PubMed ID: 3398239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
    Verlinden NJ; Coons JC
    Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
    Sirak TE; Sherrid MV
    Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
    Haruki S; Minami Y; Suzuki A; Hagiwara N
    Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation.
    Gondo N; Kumagai K; Yamanouchi Y; Annoura M; Saku K
    J Cardiol; 2000 Dec; 36(6):405-10. PubMed ID: 11190584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
    Tokudome T; Mizushige K; Ueda T; Sakamoto S; Matsuo H
    Angiology; 1999 Apr; 50(4):331-5. PubMed ID: 10225470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial tachyarrhythmias after cardiac surgery: results of disopyramide therapy.
    Gavaghan TP; Feneley MP; Campbell TJ; Morgan JJ
    Aust N Z J Med; 1985 Feb; 15(1):27-32. PubMed ID: 3859260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy.
    Stafford WJ; Trohman RG; Bilsker M; Zaman L; Castellanos A; Myerburg RJ
    J Am Coll Cardiol; 1986 Mar; 7(3):701-4. PubMed ID: 3950248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis.
    Hirose K; Yamaguchi H; Oshima Y; Choraku M; Hirono A; Takamori N; Tamura K
    Intern Med; 2008; 47(19):1703-8. PubMed ID: 18827420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular collapse associated with disopyramide therapy.
    Desai JM; Scheinman MM; Hirschfeld D; Gonzalez R; Peters RW
    Chest; 1981 May; 79(5):545-51. PubMed ID: 7226932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
    Niki K; Sugawara M; Tanino S; Iwade K; Hosoda S; Kasanuki H
    Heart Vessels; 1999; 14(2):72-81. PubMed ID: 10651183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation.
    Capucci A; Piangerelli L; Ricciotti J; Gabrielli D; Guerra F
    Europace; 2016 Nov; 18(11):1698-1704. PubMed ID: 26893497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical studies of Norpace (Part IV).
    Jutzy RV
    Angiology; 1975 Jan; 26(1 Pt 2):138-9. PubMed ID: 803798
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of disturbances of cardiac rhythm using intravenous disopyramide].
    Lisin N; Andriange M; Vandenbosch R; Carlier J
    Rev Med Liege; 1974 May; 29(9):256-64. PubMed ID: 4134825
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias.
    Stewart DE; Ikram H
    N Z Med J; 1984 Mar; 97(751):148-50. PubMed ID: 6584758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Miller CAS; Maron MS; Estes NAM; Price LL; Rowin EJ; Maron BJ; Link MS
    Am J Cardiol; 2019 Jun; 123(11):1859-1862. PubMed ID: 30922542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.